Advertisement

Familiäres Melanom

  • Claus Garbe
  • Birgit Schittek
Part of the Molekulare Medizin book series (MOLMED)

Zusammenfassung

Bereits 1820 wurde von W. A. Norris ein erster Fall eines familiären Melanoms in englischer Sprache beschrieben (Norris 1820). Dabei wurde bereits herausgestellt, dass familiär auffällige Muttermale vorhanden waren, und eine Erblichkeit des Tumorleidens angenommen:

„It is remarkable that this gentleman’s father, about thirty years ago, died of a similar disease. A surgeon of this town attended him, and he informed me that a number of small tumours appeared between the shoulders… This tumour, I have remarked, originated in a mole, and it is worth mentioning, that not only my patient, and his children had many moles on various parts of their bodies, but also his own father and brothers had many of them. The youngest son had one of these marks exactly in the same place where the disease in his father first manifested itself. These facts, together with a case that has come under my notice, rather similar, would incline me to believe that this disease is hereditary.“ (Norris 1820).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ackerman AB (1988) What naevus is dysplastic, a syndrome and the commonest precursor of malignant melanoma? A riddle and an answer. Histopathology 13:241–256PubMedGoogle Scholar
  2. Ackerman AB, Milde P (1992) Naming acquired melanocytic nevi. Common and dysplastic, normal and atypical, or Unna, Miescher, Spitz, and Clark? Am J Dermatopathol 14:447–453PubMedGoogle Scholar
  3. Aitken J, Welch J, Duffy D et al. (1999) CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 91:446–452PubMedGoogle Scholar
  4. Anderson DE, Smith JLJ, McBride CM (1967) Hereditary aspects of malignant melanoma. JAMA 200:741–746PubMedGoogle Scholar
  5. Ang CG, Kelly JW, Fritschi L, Dowling JP (1998) Characteristics of familial and non-familial melanoma in Australia. Melanoma Res 8:459–464PubMedGoogle Scholar
  6. Bale SJ, Greene MH, Murray C, Goldin LR, Johnson AH, Mann D (1985) Hereditary malignant melanoma is not linked to the HLA complex on chromosome 6. Int J Cancer 36:439–443PubMedGoogle Scholar
  7. Bale SJ, Dracopoli NC, Tucker MA et al. (1989) Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 320:1367–1372PubMedGoogle Scholar
  8. Barger BO, Acton RT, Soong SJ, Roseman J, Balch C (1982) Increase of HLA-DR4 in melanoma patients from Alabama. Cancer Res 42:4276–4279PubMedGoogle Scholar
  9. Barnhill RL, Roush GC (1991) Correlation of clinical and histopathologic features in clinically atypical melanocytic nevi. Cancer 67:3157–3164PubMedGoogle Scholar
  10. Barnhill RL, Roush GC, Duray PH (1990) Correlation of histologic architectural and cytoplasmic features with nuclear atypia in atypical (dysplastic) nevomelanocytic nevi. Hum Pathol 21:51–58PubMedGoogle Scholar
  11. Bataille V, Bishop JA, Sasieni P et al. (1996) Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer 73:1605–1611PubMedGoogle Scholar
  12. Bergman W, Watson P, Jong J de, Lynch HT, Fusaro RM (1990) Systemic cancer and the FAMMM syndrome. Br J Cancer 61:932–936PubMedGoogle Scholar
  13. Bergman W, Gruis NA, Sandkuijl LA, Frants RR (1994) Genetics of seven Dutch familial atypical multiple molemelanoma syndrome families: a review of linkage results including chromosomes 1 and 9. J Invest Dermatol 103:122S–125SPubMedGoogle Scholar
  14. Bliss JM, Ford D, Swerdlow AJ et al. (1995) Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer 62:367–376PubMedGoogle Scholar
  15. Borg A, Johannsson U, Johannsson O et al. (1996) Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res 56:2497–2500PubMedGoogle Scholar
  16. Bressac-de Pillerets B, Soufir N, Chompret A (1997) Germ-line mutations in p16 and CDK4 genes in 38 melanoma families. Melanoma Res 7:S132Google Scholar
  17. Cairns P, Mao L, Merlo A et al. (1994) Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:415–417PubMedGoogle Scholar
  18. Cannon AL, Goldgar DE, Wright EC et al. (1990) Evidence against the reported linkage of the cutaneous melanomadysplastic nevus syndrome locus to chromosome Ip36. Am J Hum Genet 46:912–918Google Scholar
  19. Cannon AL, Goldgar DE, Meyer LJ et al. (1992) Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258:1148–1152Google Scholar
  20. Carey WP Jr, Thompson CJ, Synnestvedt M et al. (1994) Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer 74:3118–3125PubMedGoogle Scholar
  21. Castellano M, Parmiani G (1999) Genes involved in melanoma: an overview of INK4a and other loci. Melanoma Res 9:421–432PubMedGoogle Scholar
  22. Cawley E (1952) Genetic aspects of malignant melanoma. Arch Dermatol 65:440–450Google Scholar
  23. Clark WH Jr, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ (1978) Origin of familial malignant melanomas from heritable melanocytic lesions. “The B-K mole syndrome”. Arch Dermatol 114:732–738PubMedGoogle Scholar
  24. Czarnecki D, Nicholson I, Tait B, Nash C (1993) HLA DR4 is associated with the development of multiple basal cell carcinomas and malignant melanoma. Dermatology 187:16–18PubMedGoogle Scholar
  25. Demetrick DJ, Zhang H, Beach DH (1994) Chromosomal mapping of human CDK2, CDK4, and CDK5 cell cycle kinase genes. Cytogenet Cell Genet 66:72–74PubMedGoogle Scholar
  26. Dracopoli NC, Fountain JW (1996) CDKN2 mutations in melanoma. Cancer Surv 26:115–132PubMedGoogle Scholar
  27. Dracopoli NC, Alhadeff B, Houghton AN, Old LJ (1987) Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma. Cancer Res 47:3995–4000PubMedGoogle Scholar
  28. Elder DE, Goldman LI, Goldman SC, Greene MH, Clark WHJ (1980) Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer 46:1787–1794PubMedGoogle Scholar
  29. FitzGerald MG, Harkin DP, Silva AS et al. (1996) Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 93:8541–8545PubMedGoogle Scholar
  30. Ford D, Bliss JM, Swerdlow AJ et al. (1995) Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int J Cancer 62:377–381PubMedGoogle Scholar
  31. Foulkes WD, Flanders TY, Pollock PM, Hayward NK (1997) The CDKN2A (p16) gene and human cancer. Mol Med 3:5–20PubMedGoogle Scholar
  32. Fountain JW, Karayiorgou M, Ernstoff MS et al. (1992) Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 89:10.557–10.561Google Scholar
  33. Garbe C, Büttner P, Weiss J et al. (1994) Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol 102:695–699PubMedGoogle Scholar
  34. Geller AC, Koh HK, Miller DR, Lew RA (1992) Practices and beliefs concerning screening family members of patients with melanoma. Results of a survey of New England dermatologists. J Am Acad Dermatol 26:419–422PubMedGoogle Scholar
  35. Goldstein AM, Tucker MA (1997) Screening for CDKN2A mutations in hereditary melanoma. J Natl Cancer Inst 89:676–678PubMedGoogle Scholar
  36. Goldstein AM, Dracopoli NC, Ho EC et al. (1993) Further evidence for a locus for cutaneous malignant melanomadysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet 52:537–550PubMedGoogle Scholar
  37. Goldstein AM, Fraser MC, Struewing JP et al. (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333:970–974PubMedGoogle Scholar
  38. Goldstein AM, Goldin LR, Dracopoli NC, Clark WHJ, Tucker MA (1996) Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi. Am J Hum Genet 58:1050–1056PubMedGoogle Scholar
  39. Grange F, Chompret A, Guilloud BM et al. (1995) Comparison between familial and nonfamilial melanoma in France. Arch Dermatol 131:1154–1159PubMedGoogle Scholar
  40. Greene MH (1999) The genetics of hereditary melanoma and nevi — 1998 update. Cancer 86:1644–1657Google Scholar
  41. Greene MH, Clark-WH J, Tucker MA, Kraemer KH, Elder DE, Fraser MC (1985) High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 102:458–465PubMedGoogle Scholar
  42. Gruis NA, Bergman W, Frants RR (1990) Locus for susceptibility to melanoma on chromosome 1p. N Engl J Med 322:853–854PubMedGoogle Scholar
  43. Gruis NA, Sandkuijl LA, Van der Velden P, Bergman W, Frants RR (1995) CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res 5:169–177PubMedGoogle Scholar
  44. Gruis NA, Van der Velden P, Sandkuijl LA et al. (1995) Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 10:351–353PubMedGoogle Scholar
  45. Gruis NA, Van der Velden P, Bergman W, Frants RR (1998) Genetics of familial atypical multiple mole-melanoma (FAMMM) syndrome in The Netherlands: how far have we come? Bull Cancer 85:627–630PubMedGoogle Scholar
  46. Gruis N, Van der Velden P, Bergmann WFR (1999) Familial melanoma; CDKN2A and beyond. J Invest Dermatol Symp Proc 4:50–54Google Scholar
  47. Grulich AE, Bataille V, Swerdlow AJ et al. (1996) Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: a case-control study in New South Wales, Australia. Int J Cancer 67:485–491PubMedGoogle Scholar
  48. Guldberg P, Kirkin AF, Gronbaek K, Thor SP, Ahrenkiel V, Zeuthen J (1997) Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. Int J Cancer 72:780–783PubMedGoogle Scholar
  49. Hamada K, Kohno T, Kawanishi M, Ohwada S, Yokota J (1998) Association of CDKN2A(p16)/CDKN2B(p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma. Genes Chromosomes Cancer 22:232–240PubMedGoogle Scholar
  50. Harland M, Meloni R, Gruis N et al. (1997) Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6:2061–2067PubMedGoogle Scholar
  51. Hawkins BR, Dawkins RL, Hockey A, Houliston JB, Kirk RL (1981) Evidence for linkage between HLA and malignant melanoma. Tissue Antigens 17:540–541PubMedGoogle Scholar
  52. Hayward NK (1996) The current situation with regard to human melanoma and genetic inferences. Curr Opin Oncol 8:136–142PubMedGoogle Scholar
  53. Herbst RA, Gutzmer R, Matiaske F et al. (1997) Further evidence for ultraviolet light induction of CDKN2 (p16INK4) mutations in sporadic melanoma in vivo. J Invest Dermatol 108:950PubMedGoogle Scholar
  54. Herbst RA, Mommert S, Schubach J, Podewski EK, Kapp A, Weiss J (1999) Allelic loss at the p73 locus (1p36.33) is infrequent in malignant melanoma. Arch Dermatol Res 291:362–364PubMedGoogle Scholar
  55. Holly EA, Aston DA, Cress RD, Ahn DK, Kristiansen JJ (1995) Cutaneous melanoma in women. II. Phenotypic characteristics and other host-related factors. Am J Epidemiol 141:934–942PubMedGoogle Scholar
  56. Hussussian CJ, Struewing JP, Goldstein AM et al. (1994) Germline p16 mutations in familial melanoma. Nat Genet 8:15–21PubMedGoogle Scholar
  57. Jadayel DM, Lukas J, Nacheva E et al. (1997) Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin’s lymphomas. Functional studies in a cell line (Granta 519). Leukemia 11:64–72PubMedGoogle Scholar
  58. Kamb A (1995) Cell-cycle regulators and cancer. Trends Genet 11:136–140PubMedGoogle Scholar
  59. Kamb A (1996) Human melanoma genetics. J Invest Dermatol Symp Proc 1:177–182Google Scholar
  60. Kamb A, Gruis NA, Weaver FJ et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440PubMedGoogle Scholar
  61. Kamb A, Shattuck ED, Eeles R et al. (1994) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:23–26PubMedGoogle Scholar
  62. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95:8292–8297PubMedGoogle Scholar
  63. Kaufmann R, Tilgen W, Garbe C (1998) Malignant melanoma. Quality Assurance Committee of the German Society of Dermatology and the Professional Organization of German Dermatologists. Hautarzt [Suppl 1] 48:S30–S38Google Scholar
  64. Kefford RF, Salmon J, Shaw HM, Donald JA, McCarthy WH (1991) Hereditary melanoma in Australia. Variable association with dysplastic nevi and absence of genetic linkage to chromosome 1p. Cancer Genet Cytogenet 51:45–55PubMedGoogle Scholar
  65. Kefford RF, Newton-Bishop JA, Bergman W, Tucker MA (1999) Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 17:3245–3251PubMedGoogle Scholar
  66. Kelly JW, Holly EA, Shpall SN, Ahn DK (1989) The distribution of melanocytic naevi in melanoma patients and control subjects. Australas J Dermatol 30:1–8PubMedGoogle Scholar
  67. Koh J, Enders GH, Dynlacht BD, Harlow E (1995) Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375:506–510PubMedGoogle Scholar
  68. Kopf AW, Friedman RJ, Rigel DS (1990) Atypical mole syndrome. J Am Acad Dermatol 22:117–118PubMedGoogle Scholar
  69. Kroiss MM, Bosserhoff AK, Vogt T et al. (1998) Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas. Melanoma Res 8:504–509PubMedGoogle Scholar
  70. Larsen CJ (1996) p16INK4a: a gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression. Oncogene 12:2041–2044PubMedGoogle Scholar
  71. Lee JY, Dong SM, Shin MS et al. (1997) Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus. Biochem Biophys Res Commun 237:667–672PubMedGoogle Scholar
  72. Lilischkis R, Sarcevic B, Kennedy C, Warlters A, Sutherland RL (1996) Cancer-associated missense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer 66:249–254PubMedGoogle Scholar
  73. Little M, Wainwright B (1995) Methylation and p16: suppressing the suppressor (comment). Nat Med 1:633–634PubMedGoogle Scholar
  74. Liu L, Lassam NJ, Slingerland JM et al. (1995) Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 11:405–412PubMedGoogle Scholar
  75. Liu L, Goldstein AM, Tucker MA et al. (1997) Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2 A do not harbor mutations in the coding regions of either CDKN2B or p19ARF. Genes Chromosomes Cancer 19:52–54PubMedGoogle Scholar
  76. Liu L, Dilworth D, Gao LZ et al. (1999) Mutation of the CDKN2A 5′ UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 21:128–132PubMedGoogle Scholar
  77. Lukas J, Aagaard L, Strauss M, Bartek J (1995) Oncogenic aberrations of p16INK4/CDKN2 and cyclin Dl cooperate to deregulate Gl control. Cancer Res 55:4818–4823PubMedGoogle Scholar
  78. Lynch HT, Frichot BC, Lynch JF (1978) Familial atypical multiple mole-melanoma syndrome. J Med Genet 15:352–356PubMedGoogle Scholar
  79. MacGeoch C, Bishop JA, Bataille V et al. (1994) Genetic heterogeneity in familial malignant melanoma. Hum Mol Genet 3:2195–2200PubMedGoogle Scholar
  80. Mao L, Merlo A, Bedi G, et al. (1995) A novel p16INK4A transcript. Cancer Res 55:2995–2997PubMedGoogle Scholar
  81. Merlo A, Herman JG, Mao L et al. (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTSl in human cancers. Nat Med 1:686–692PubMedGoogle Scholar
  82. Monzon J, Liu L, Brill H et al. (1998) CDKN2A mutations in multiple primary melanomas. N Engl J Med 338:879–887PubMedGoogle Scholar
  83. Mueller EG, Schendel DJ, Hundeiker M et al. (1984) Possible association between HLA-DR5 and superficial spreading melanoma (SSM). Int J Cancer 34:751–755Google Scholar
  84. Nancarrow DJ, Palmer JM, Walters MK et al. (1992) Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome arm 1p in 7 Australian pedigrees. Genomics 12:18–25PubMedGoogle Scholar
  85. Nancarrow DJ, Mann GJ, Holland EA et al. (1993) Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet 53:936–942PubMedGoogle Scholar
  86. Nelson MA, Ariza ME, Yang JM et al. (1999) Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma. Cancer Genet Cytogenet 108:91–99PubMedGoogle Scholar
  87. Newton JA (1993) Familial melanoma. Clin Exp Dermatol 18:5–11PubMedGoogle Scholar
  88. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753–756PubMedGoogle Scholar
  89. Norris W (1820) A case of fungoid disease. Edinb Med Surg J 16:562–565Google Scholar
  90. Parry D, Peters G (1996) Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol 16:3844–3852PubMedGoogle Scholar
  91. Pellegris G, Illeni MT, Rovini D, Vaglini M, Cascinelli N, Ghidoni A (1982) HLA complex and familial malignant melanoma. Int J Cancer 29:621–623PubMedGoogle Scholar
  92. Piccinin S, Doglioni C, Maestro R et al. (1997) p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int J Cancer 74:26–30PubMedGoogle Scholar
  93. Ping YJ, Nakatsu Y, Goldstein AM, Tucker MA, Kraemer KH, Tanaka K (1998) RPA2, a gene for the 32 kDa subunit of replication protein A on chromosome 1p35-36, is not mutated in patients with familial melanoma linked to chromosome 1p36. Melanoma Res 8:47–52PubMedGoogle Scholar
  94. Platz A, Hansson J, Mansson BE et al. (1997) Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 89:697–702PubMedGoogle Scholar
  95. Platz A, Hansson J, Ringborg U (1998) Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study. Int J Cancer 78:13–15PubMedGoogle Scholar
  96. Pollack MS, Livingston PO (1985) HLA and DR antigen frequencies in melanoma patients: possible relation to disease prognosis. Tissue Antigens 26:262–265PubMedGoogle Scholar
  97. Pollock PM, Spurr N, Bishop T et al. (1998) Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat 11:424–431PubMedGoogle Scholar
  98. Pomerantz J, Schreiber AN, Liégeois NJ et al. (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 92:713–723PubMedGoogle Scholar
  99. Provost N, Kopf AW, Rabinovitz HS et al. (1998) Comparison of conventional photographs and telephonically transmitted compressed digitized images of melanomas and dysplastic nevi. Dermatology 196:299–304PubMedGoogle Scholar
  100. Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993–1000PubMedGoogle Scholar
  101. Quelle DE, Cheng M, Ashmun RA, Sherr CJ (1997) Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc Natl Acad Sci USA 94:669–673PubMedGoogle Scholar
  102. Rahbari H, Mehregan AH (1981) Sporadic atypical mole syndrome. A report of five nonfamilial B-K mole syndrome-like cases and histopathologic findings. Arch Dermatol 117:329–331PubMedGoogle Scholar
  103. Ranade K, Hussussian CJ, Sikorski RS et al. (1995) Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 10:114–116PubMedGoogle Scholar
  104. Reymond A, Brent R (1995) p16 proteins from melanomaprone families are deficient in binding to Cdk4. Oncogene 11:1173–1178PubMedGoogle Scholar
  105. Roth ME, Grant KJ, Ackerman AB et al. (1991) The histopathology of dysplastic nevi. Continued controversy. Am J Dermatopathol 13:38–51PubMedGoogle Scholar
  106. Schittek B, Sauer B, Garbe C (1999) Lack of p73 mutations and late occurrence of p73 allelic deletions in melanoma tissues and cell lines. Int J Cancer 82:583–586PubMedGoogle Scholar
  107. Serrano M (1997) The tumor suppressor protein p16INK4a. Exp Cell Res 237:7–13PubMedGoogle Scholar
  108. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707PubMedGoogle Scholar
  109. Serrano M, Lee H, Chin L, Cordon CC, Beach D, DePinho RA (1996) Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27–37PubMedGoogle Scholar
  110. Sigg C, Pelloni F, Schnyder UW (1989) Gehäufte Mehrfachmelanome bei sporadischem und familiärem dysplastischen Nävuszellnävus-Syndrom. Hautarzt 40:548–552PubMedGoogle Scholar
  111. Slue W, Kopf AW, Rivers JK (1988) Total-body photographs of dysplastic nevi. Arch Dermatol 124:1239–1243PubMedGoogle Scholar
  112. Smith E, Henley W, Knox J, Lane M (1966) Familial melanoma. Arch Intern Med 117:820–823PubMedGoogle Scholar
  113. Soufir N, Avril MF, Chompret A et al. (1998) Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 7:209–216PubMedGoogle Scholar
  114. Stadler WM, Olopade OI (1996) The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes. Urol Res 24:239–244PubMedGoogle Scholar
  115. Stone S, Dayananth P, Jiang P et al. (1995) Genomic structure, expression and mutational analysis of the P15 (MTS2) gene. Oncogene 11:987–991PubMedGoogle Scholar
  116. Stone S, Jiang P, Dayananth P et al. (1995) Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55:2988–2994PubMedGoogle Scholar
  117. Stott FJ, Bates S, James MC et al. (1998) The alternative product from the human CDKN2A locus, pl4(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17:5001–5014PubMedGoogle Scholar
  118. Suzuki H, Zhou X, Yin J et al. (1995) Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers. Hum Mol Genet 4:1883–1887PubMedGoogle Scholar
  119. Tsao H, Sober AJ (1998) Ultraviolet radiation and malignant melanoma. Clin Dermatol 16:67–73PubMedGoogle Scholar
  120. Tsao H, Benoit E, Sober AJ, Thiele C, Haluska FG (1998) Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res 58:109–113PubMedGoogle Scholar
  121. Tsao H, Zhang X, Majewski P, Haluska FG (1999) Mutational and expression analysis of the p73 gene in melanoma cell lines. Cancer Res 59:172–174PubMedGoogle Scholar
  122. Tucker MA, Halpern A, Holly EA et al. (1997) Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 277:1439–1444PubMedGoogle Scholar
  123. Turkington R (1965) Familial factors in malignant melanoma. JAMA 192:77–82PubMedGoogle Scholar
  124. Valverde P, Healy E, Sikkink S et al. (1996) The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 5:1663–1666PubMedGoogle Scholar
  125. Van Haeringen A, Bergman W, Nelen MR et al. (1989) Exclusion of the dysplastic nevus syndrome (DNS) locus from the short arm of chromosome 1 by linkage studies in Dutch families. Genomics 5:61–64PubMedGoogle Scholar
  126. Walker GJ, Nancarrow DJ, Walters MK, Palmer JM, Weber JL, Hayward NK (1994) Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int J Cancer 59:771–775PubMedGoogle Scholar
  127. Walker GJ, Hussussian CJ, Flores JF et al. (1995) Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 4:1845–1852PubMedGoogle Scholar
  128. Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, Fountain JW (1998) Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 22:157–163PubMedGoogle Scholar
  129. Wang Y, Becker D (1996) Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system. Oncogene 12:1069–1075PubMedGoogle Scholar
  130. Weaver FJ, Gruis NA, Neuhausen S et al. (1994) Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. Proc Natl Acad Sci USA 91:7563–7567Google Scholar
  131. Wolfel T, Hauer M, Schneider J et al. (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281–1284PubMedGoogle Scholar
  132. Yang R, Gombart AF, Serrano M, Koeffler HP (1995) Mutational effects on the p16INK4a tumor suppressor protein. Cancer Res 55:2503–2506PubMedGoogle Scholar
  133. Zuo L, Weger J, Yang Q et al. (1996) Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97–99PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • Claus Garbe
    • 1
  • Birgit Schittek
    • 1
  1. 1.Sektion für Dermatologische OnkologieUniversitätshautklinikTübingen

Personalised recommendations